{"id":12390,"date":"2026-07-30T09:02:29","date_gmt":"2026-07-30T09:02:29","guid":{"rendered":"https:\/\/villpress.com\/?p=12390"},"modified":"2026-07-30T09:02:55","modified_gmt":"2026-07-30T09:02:55","slug":"medidata-launches-ai-native-platform","status":"publish","type":"post","link":"https:\/\/villpress.com\/de\/medidata-launches-ai-native-platform\/","title":{"rendered":"Medidata Launches AI Native Platform to Expand Clinical Trial Automation"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Medidata, a subsidiary of Dassault Syst\u00e8mes, has launched Medidata Plus, a new artificial intelligence driven platform aimed at helping life sciences companies scale AI across clinical trial portfolios as the pharmaceutical industry accelerates its adoption of data driven drug development. The company announced the launch as part of its broader strategy to integrate AI throughout the clinical research lifecycle.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">According to Medidata, Medidata Plus serves as an AI layer built on its existing clinical research platform, connecting study operations, patient data and analytics through a unified system. The platform is intended to enable pharmaceutical companies, biotechnology firms and contract research organisations to automate workflows, identify operational risks earlier and improve decision making across multiple clinical programmes rather than managing individual trials in isolation.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The launch builds on Medidata\u2019s expanding investment in artificial intelligence. Earlier this year, the company said its AI technologies had supported more than 500 clinical studies over the past decade, with increasing adoption among biopharmaceutical companies seeking to shorten study timelines and improve trial efficiency. It has also expanded partnerships with contract research organisations to embed AI throughout study design, patient recruitment, data management and trial execution.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Clinical trials have become increasingly complex, with sponsors facing rising development costs, growing regulatory requirements and mounting pressure to bring new medicines to market more quickly. Industry estimates suggest the average development timeline for a new therapy can extend beyond a decade, making AI powered tools an area of growing interest for pharmaceutical companies looking to reduce delays and improve operational efficiency.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Medidata said the platform is powered by Dot, its virtual AI companion, which draws on validated clinical data generated across tens of thousands of trials. The company says the system can provide explainable and auditable recommendations, helping research teams manage study performance while meeting regulatory expectations. These capabilities are designed specifically for regulated clinical research rather than general purpose AI applications.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The launch also reflects a broader shift across the healthcare technology industry, where software providers are increasingly embedding generative AI and predictive analytics into research platforms. Companies including Oracle Health, IQVIA and Veeva Systems have expanded their own AI offerings as pharmaceutical companies seek technology that can accelerate drug discovery and clinical development while maintaining compliance with strict regulatory standards.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">For Medidata, the introduction of Medidata Plus strengthens its position in the competitive clinical trial software market, where providers are moving beyond digital record keeping to offer AI powered decision support. The company argues that connecting AI across entire research portfolios could help sponsors identify risks earlier, improve resource allocation and shorten study timelines.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Investors and industry participants will now watch how quickly pharmaceutical companies adopt the new platform and whether enterprise wide AI deployments translate into measurable improvements in clinical trial productivity and drug development timelines.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><a href=\"https:\/\/villpress.com\/support-villpress\/\"><img loading=\"lazy\" decoding=\"async\" width=\"926\" height=\"365\" src=\"https:\/\/villpress.com\/wp-content\/uploads\/2026\/05\/Support-Villpress-Journalism-new.png\" alt=\"Support Villpress Journalism\" class=\"wp-image-10783\" \/><\/a><\/figure>","protected":false},"excerpt":{"rendered":"<p>Medidata, a subsidiary of Dassault Syst\u00e8mes, has launched Medidata Plus, a new artificial intelligence driven platform aimed at helping life sciences companies scale AI across clinical trial portfolios as the pharmaceutical industry accelerates its adoption of data driven drug development. The company announced the launch as part of its broader strategy to integrate AI throughout [&hellip;]<\/p>\n","protected":false},"author":31579,"featured_media":12398,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_mi_skip_tracking":false,"footnotes":""},"categories":[64],"tags":[65,2271],"ppma_author":[452],"class_list":["post-12390","post","type-post","status-publish","format-standard","has-post-thumbnail","category-ai","tag-artificial-intelligence","tag-medidata"],"acf":[],"authors":[{"term_id":452,"user_id":31579,"is_guest":0,"slug":"estherspeaks","display_name":"Esthy Speaks","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/cdcaf0f94087bbfcad372d974a1a697382dc93112457104ff6535cf4984ea4de?s=96&d=mm&r=g","author_category":"1","first_name":"Esthy","last_name":"Speaks","user_url":"https:\/\/villpress.com\/","job_title":"","description":"Ester Speaks is a senior reporter and newsroom strategist at Villpress, where she shapes Africa-focused business, technology, and policy coverage.\u00a0 She works at the intersection of journalism, and editorial systems, producing clear, high-impact news that travels globally while staying rooted in African realities."}],"_links":{"self":[{"href":"https:\/\/villpress.com\/de\/wp-json\/wp\/v2\/posts\/12390","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/villpress.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/villpress.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/villpress.com\/de\/wp-json\/wp\/v2\/users\/31579"}],"replies":[{"embeddable":true,"href":"https:\/\/villpress.com\/de\/wp-json\/wp\/v2\/comments?post=12390"}],"version-history":[{"count":1,"href":"https:\/\/villpress.com\/de\/wp-json\/wp\/v2\/posts\/12390\/revisions"}],"predecessor-version":[{"id":12399,"href":"https:\/\/villpress.com\/de\/wp-json\/wp\/v2\/posts\/12390\/revisions\/12399"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/villpress.com\/de\/wp-json\/wp\/v2\/media\/12398"}],"wp:attachment":[{"href":"https:\/\/villpress.com\/de\/wp-json\/wp\/v2\/media?parent=12390"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/villpress.com\/de\/wp-json\/wp\/v2\/categories?post=12390"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/villpress.com\/de\/wp-json\/wp\/v2\/tags?post=12390"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/villpress.com\/de\/wp-json\/wp\/v2\/ppma_author?post=12390"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}